1. Home
  2. OCSL vs RVMDW Comparison

OCSL vs RVMDW Comparison

Compare OCSL & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCSL
  • RVMDW
  • Stock Information
  • Founded
  • OCSL 2007
  • RVMDW N/A
  • Country
  • OCSL United States
  • RVMDW United States
  • Employees
  • OCSL N/A
  • RVMDW 443
  • Industry
  • OCSL Finance: Consumer Services
  • RVMDW
  • Sector
  • OCSL Finance
  • RVMDW
  • Exchange
  • OCSL Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • OCSL N/A
  • RVMDW N/A
  • IPO Year
  • OCSL 2008
  • RVMDW N/A
  • Fundamental
  • Price
  • OCSL $16.01
  • RVMDW $0.61
  • Analyst Decision
  • OCSL Buy
  • RVMDW
  • Analyst Count
  • OCSL 7
  • RVMDW 0
  • Target Price
  • OCSL $18.17
  • RVMDW N/A
  • AVG Volume (30 Days)
  • OCSL 514.4K
  • RVMDW N/A
  • Earning Date
  • OCSL 11-19-2024
  • RVMDW N/A
  • Dividend Yield
  • OCSL 13.75%
  • RVMDW N/A
  • EPS Growth
  • OCSL N/A
  • RVMDW N/A
  • EPS
  • OCSL 0.85
  • RVMDW N/A
  • Revenue
  • OCSL $388,874,000.00
  • RVMDW N/A
  • Revenue This Year
  • OCSL $3.72
  • RVMDW N/A
  • Revenue Next Year
  • OCSL $1.22
  • RVMDW N/A
  • P/E Ratio
  • OCSL $18.92
  • RVMDW N/A
  • Revenue Growth
  • OCSL 11.90
  • RVMDW N/A
  • 52 Week Low
  • OCSL $15.55
  • RVMDW N/A
  • 52 Week High
  • OCSL $21.64
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • OCSL 45.21
  • RVMDW N/A
  • Support Level
  • OCSL $15.55
  • RVMDW N/A
  • Resistance Level
  • OCSL $16.45
  • RVMDW N/A
  • Average True Range (ATR)
  • OCSL 0.27
  • RVMDW 0.00
  • MACD
  • OCSL -0.02
  • RVMDW 0.00
  • Stochastic Oscillator
  • OCSL 49.46
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: